Scarica l'app Stockscreener
65.51
1.71%
1.10
Dopo l'orario di chiusura:
65.00
-0.51
-0.78%
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
BMRN: Blockbuster growth, pipeline innovation, and AI-driven efficiencies drive future outlook - TradingView
BioMarin at Citi summit: voxzogo drives growth as pipeline widens By Investing.com - Investing.com India
BMRN: Portfolio expansion, robust growth, and pipeline innovation drive long-term outlook - TradingView
BioMarin at Cantor conference: growth plan widens beyond Voxzogo By Investing.com - Investing.com India
Ascendis Pharma Says Growth Drug Shows Benefits in Infants - Benzinga
H.C. Wainwright reiterates Biomarin stock rating at neutral - Investing.com
H.C. Wainwright reiterates Biomarin stock rating at neutral By Investing.com - Investing.com India
BioMarin at Wells Fargo conference: growth, pipeline and integration By Investing.com - Investing.com India
BMRN: Strong growth, pipeline expansion, and global market execution drive future momentum - TradingView
(BMRN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
BioMarin Pharmaceutical Inc. Announces Positive Results Of Phase 3 VOXZOGO Study In Hypochondroplasia - marketscreener.com
BioMarin Announces Positive Results of Phase 3 VOXZOGO® Study in Hypochondroplasia Published in NEJM Evidence - Investing News Network
Ten healthcare stocks with A-rated valuations and strong revenue growth - TradingView
A drug helped children with a rare growth disorder grow 2.33 cm more per year - Stock Titan
Don't Ignore The Insider Selling In BioMarin Pharmaceutical - simplywall.st
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout - Stocktwits
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC - Yahoo Finance
3 Reasons to Avoid BMRN and 1 Stock to Buy Instead - Yahoo Finance
Royalty Deal Could Be A Big Development For BioMarin Stock (BMRN) - simplywall.st
Weekly Recap: TransCon CNP license and Alesta Therapeutics acquisition - TradingView
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: 37% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
BioMarin Pharmaceutical (BMRN), What Is Behind The Fresh Attention? - simplywall.st
BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It? - Yahoo Finance
EVP At BioMarin Pharmaceutical Sells $1.16M Of Stock - Benzinga
Ascendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement Backing - Yahoo Finance
BioMarin (NASDAQ: BMRN) legal chief unloads 17,557 shares - Stock Titan
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset - Eastern Progress
Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A TargetUltragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga
Officer at BioMarin (NASDAQ: BMRN) plans sale of 17,557 shares - Stock Titan
BioMarin to Participate in Upcoming Investor Conferences - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), BioMarin Pharmaceutical (BMRN) and Envista Holdings (NVST) - The Globe and Mail
CASI Pharmaceuticals (CASIF) sells Alesta stake to BioMarin, with possible future milestone payouts - Stock Titan
How BioMarin’s Navepegritide Settlement and Royalty Deal with Ascendis Could Shape BioMarin (BMRN) Investors - simplywall.st
Piper Sandler raises BioMarin stock price target on IP settlement By Investing.com - Investing.com South Africa
BioMarin To Get Royalties From Ascendis Under IP Settlement - Law360
Oppenheimer raises Ascendis Pharma stock price target on settlement - Investing.com
BioMarin announces global settlement with Ascendis - The Pharma Letter
BioMarin Completes Alesta Therapeutics Acquisition, Adding HPP Drug Candidate ALE1 - citybiz
BioMarin Announces Close of the Alesta Therapeutics Acquisition - Investing News Network
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects - Eastern Progress
Piper Sandler raises BioMarin stock price target on IP settlement - Investing.com
BioMarin completes acquisition of Alesta, making it a wholly owned subsidiary - TradingView
Canaccord reiterates BioMarin stock rating on Ascendis settlement By Investing.com - Investing.com Australia
Canaccord reiterates BioMarin stock rating on Ascendis settlement - Investing.com
BioMarin Secures Double-Digit Yuviwel Royalties In Settlement With Ascendis - insights.citeline.com
Ascendis Pharma (NASDAQ: ASND) strikes global YUVIWEL settlement with BioMarin - stocktitan.net
Ascendis Pharma A/S and Biomarin Pharmaceutical Inc. Enter Binding Term Sheet for Global Settlement and License Agreement Related to Yuviwel and Navepegritide-Related Products - marketscreener.com
Morgan Stanley reiterates BioMarin stock rating on settlement value By Investing.com - Investing.com Nigeria
Ascendis pays 20% royalties in patent settlement with BioMarin - fiercepharma.com
BioMarin Pharma gains with analyst upgrade, pat... - Pluang
Jefferies raises BioMarin stock price target on Ascendis settlement - Investing.com
Morgan Stanley reiterates BioMarin stock rating on settlement value - Investing.com
Raymond James raises BioMarin stock price target on patent settlement By Investing.com - Investing.com Nigeria
Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis - BioSpace
Stifel holds BioMarin stock rating, keeps $70 target on IP deal - Investing.com Nigeria
BioMarin and Ascendis Pharma Finalize Patent Settlement with Royalty License Agreement - Kalkine Media
Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday - Benzinga
Ascendis Pharma Stock (ASND) Soars 7% on a Settlement with BioMarin Pharmaceutical (BMRN) - TipRanks
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes - Yahoo Finance
BioMarin stock jumps after Ascendis patent settlement deal By Investing.com - Investing.com Nigeria
BioMarin stock jumps after Ascendis patent settlement deal - Investing.com
BioMarin Licenses CNP Program to Ascendis With 20%/18% Royalties, Ends Patent Disputes - TradingView
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide) - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Unpacking a 40.78% Potential Upside - DirectorsTalk Interviews
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea - Investing News Network
BioMarin Pharmaceutical Inc. completed the acquisition of Alesta Therapeutics B.V. from a group of shareholders. - marketscreener.com
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):